エピソード

  • Metastatic Triple-Negative Breast Cancer — Oncology Q&A for Clinicians: Discussing Common Questions Posed by Patients
    2025/01/24

    Featuring perspectives from Dr Lisa Carey and Dr Rita Nanda, including the following topics:

    • Introduction (0:00)
    • Patient Videos and Clinical Investigator Survey (3:26)
    • San Antonio Breast Cancer Symposium (SABCS®) Report — Education Session on Antibody-Drug Conjugates (26:03)
    • Patient Videos and Clinical Investigator Survey (43:27)
    • SABCS Report — Abstracts of Interest (55:56)
    • Patient Videos and Clinical Investigator Survey (56:27)

    CME information and select publications

    続きを読む 一部表示
    1 時間
  • Metastatic Triple-Negative Breast Cancer | Oncology Q&A for Patients with Metastatic Triple-Negative Breast Cancer
    2025/01/17

    Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics:

    • Introduction (0:00)
    • Stages of Triple-Negative Breast Cancer (TNBC); Recurrence After Adjuvant Treatment (5:28)
    • Long-Term Outcomes with Metastatic TNBC (11:55)
    • Side Effects and Complications of Treatment (24:42)
    • Dose Reduction (30:27)
    • Working While Receiving Treatment (32:24)
    • Support for Minor Children and Grandchildren (37:12)
    • Second Opinions and Self Advocacy (42:53)
    • Recording Clinic Visits; Complementary Therapies; Nutrition (48:38)
    • Living Wills and Advanced Directives (55:41)

    Please take our survey

    続きを読む 一部表示
    1 時間 1 分
  • Lymphoma | What Clinicians Want to Know: Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma
    2025/01/16

    Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie, Prof Martin Hutchings, Dr Matthew Lunning and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics:

    • Introduction (0:00)
    • Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Abramson (2:17)
    • Bispecific Antibody Therapy for DLBCL — Prof Hutchings (28:51)
    • CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Lunning (52:01)
    • Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:17:46)
    • Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy — Dr Crombie (1:41:44)

    CME information and select publications

    続きを読む 一部表示
    2 時間
  • Myelofibrosis | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Myelofibrosis
    2025/01/14

    Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics:

    • Introduction (0:00)
    • Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Kuykendall (2:53)
    • Managing MF for Patients with Thrombocytopenia — Dr Bose (32:45)
    • Managing MF for Patients with Anemia — Dr Yacoub (59:47)
    • Future Directions in the Management of MF — Dr Fleischman (1:27:53)

    CME information and select publications

    続きを読む 一部表示
    1 時間 59 分
  • Metastatic Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of Metastatic Breast Cancer
    2025/01/10

    Featuring perspectives from Dr Erika Hamilton, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O’Shaughnessy and Dr Sara M Tolaney, including the following topics:

    • Introduction (0:00)
    • Optimizing the Care of Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Dr Krop (10:17)
    • Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr Tolaney (37:54)
    • Integrating Novel Agents and Approaches into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Kalinsky (53:59)
    • Tolerability Considerations with Approved and Investigational Antibody-Drug Conjugates — Dr O’Shaughnessy (1:14:16)
    • Other Important Care Considerations for Patients with mBC — Dr Hamilton (1:41:30)

    CME information and select publications

    続きを読む 一部表示
    2 時間 1 分
  • Chronic Myeloid Leukemia | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia
    2025/01/09

    Featuring perspectives from Prof Andreas Hochhaus, Dr Michael J Mauro and Dr B Douglas Smith, moderated by Dr Mauro, including the following topics:

    • Introduction (0:00)
    • Up-Front Therapy for Chronic Myeloid Leukemia (CML) — Prof Hochhaus (2:45)
    • Management of Relapsed CML, Including in Patients with a T315I Mutation — Dr Mauro (29:23)
    • Tolerability and Other Practical Issues with Commonly Employed CML Therapies — Dr Smith (1:00:15)

    CME information and select publications

    続きを読む 一部表示
    1 時間 27 分
  • Acute Myeloid Leukemia | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia
    2025/01/07

    Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics:

    • Introduction (0:00)
    • Treatment for Older Patients with Acute Myeloid Leukemia (AML) — Prof Wei (2:48)
    • Selection of Initial Therapy for Younger Patients with AML without a Targetable Mutation, Including Those with Secondary AML — Dr Stone (26:52)
    • Role of FLT3 Inhibitors in AML Management — Dr Perl (49:41)
    • Incorporation of IDH Inhibitors into the Care of Patients with AML — Dr Stein (1:13:57)
    • Potential Role of Menin Inhibitors and Other Novel Agents in the Treatment of AML — Dr Wang (1:35:50)

    CME information and select publications

    続きを読む 一部表示
    1 時間 59 分
  • Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer
    2025/01/03

    Featuring perspectives from Dr Matthew P Goetz, Dr Sara A Hurvitz, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Seth Wander, including the following topics:

    • Introduction (0:00)
    • Role of CDK4/6 Inhibitors in Hormone Receptor (HR)-Positive Localized Breast Cancer — Dr Hurvitz (12:21)
    • Incorporation of CDK4/6 Inhibitors into the Management of HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Wander (34:36)
    • Evolving Role of PI3K Inhibitors for HR-Positive mBC Harboring PIK3CA Mutations — Dr Goetz (57:58)
    • Clinical Utility of AKT Inhibitors for Patients with Progressive HR-Positive mBC — Dr Jhaveri (1:15:52)
    • Oral SERDs (Selective Estrogen Receptor Degraders) for HR-Positive mBC — Dr Kaklamani (1:37:24)

    CME information and select publications

    続きを読む 一部表示
    2 時間 1 分